Boehringer Ingelheim, Zealand’s positive Phase 2 MASH fibrosis data ‘unintentionally’ released

Boehringer Ingelheim and Zealand Pharma’s survodutide has improved liver scarring in a Phase 2 test in patients with metabolic dysfunction-associated steatohepatitis, or MASH, according to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

‘Search mode’: Human challenge trial company looks to buy small CROs

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 18, 2024

CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities – Biotech Investments

Issuer: CureVac / Key word(s): Restructure of Company/Strategic Company Decision 03.07.2024 / 08:12 CET/CEST The issuer is solely responsible for the content of this announcement.

July 4, 2024

Colorado moves to connect agricultural workers with mental health resources

Colorado lawmakers have proposed a pair of measures they say will improve the availability of mental health resources for the state’s agricultural industry, as stress,

February 7, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.